Welcome to our dedicated page for Rapid Micro Biosystems news (Ticker: RPID), a resource for investors and traders seeking the latest updates and insights on Rapid Micro Biosystems stock.
Rapid Micro Biosystems, Inc. (NASDAQ: RPID) is a life sciences technology company that regularly issues news and updates related to its automated microbial quality control (MQC) solutions for pharmaceutical and biopharmaceutical manufacturing. Company press releases focus on the performance and adoption of its flagship Growth Direct system, which automates and modernizes manual MQC testing workflows used in large and complex pharmaceutical manufacturing operations across the globe.
News for RPID often covers quarterly and annual financial results, including product revenue, service revenue, and recurring revenue from consumables and annual service contracts. The company highlights metrics such as system placements, customer system validations, recurring revenue growth, and record consumable revenue. Updates have also described record multi-system orders from an existing Top 20 global biopharma customer to automate a global manufacturing network across North America, Europe, and Asia Pacific.
Investors and industry followers can also expect announcements about capital structure and financing, such as the disclosed five-year, $45 million term loan facility with Trinity Capital Inc., as well as news on the company’s financial position and outlook. Additional news items include participation in major healthcare and investor conferences, including the J.P. Morgan Healthcare Conference, the Stifel Healthcare Conference, and the H.C. Wainwright Global Investment Conference, where management presents and engages with analysts and investors.
This RPID news page on Stock Titan aggregates these types of updates so readers can quickly review earnings announcements, financing developments, system placement milestones, and conference participation related to Rapid Micro Biosystems. Users interested in the evolution of automated microbial quality control in biopharma manufacturing can monitor this feed for the company’s latest publicly released information.
Rapid Micro Biosystems (Nasdaq: RPID) announced participation in the Cowen 43rd Annual Health Care Conference in Boston on March 8, 2023. The Company's President and CEO Rob Spignesi, along with CFO Sean Wirtjes, will engage in a 30-minute Q&A session starting at 9:10 a.m. Eastern Time. A live webcast will be available on the Company’s investor relations website and can be replayed for 90 days post-event. Rapid Micro Biosystems specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control with its Growth Direct System. This innovation supports faster results, greater accuracy, and compliance in the production of biologics and vaccines.
Rapid Micro Biosystems (Nasdaq: RPID) will announce its fourth quarter and full year 2022 financial results on March 3, 2023, before market opening. A webcast conference call is scheduled for 8:30 a.m. EST on the same day, with live access via the company's website. The company specializes in automation solutions for the healthcare sector, enhancing the manufacturing and quality control of products such as biologics and vaccines. Their flagship Growth Direct System facilitates faster, more accurate microbial quality control testing, improving operational efficiency and compliance in pharmaceutical manufacturing.
Rapid Micro Biosystems (Nasdaq: RPID) has announced its preliminary unaudited 2022 revenue, expecting total commercial revenue between $17.0 million and $17.2 million. The company finished 2022 with about $140 million in cash, providing operational runway until at least 2026. In Q4 2022, expected revenue is between $4.2 and $4.4 million, with notable placements of two Growth Direct systems and the addition of new global pharma customers. The company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023.
Rapid Micro Biosystems announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:45 AM PT (12:45 PM ET). The company will discuss its innovative automation solutions for healthcare manufacturing. A live webcast will be accessible on the Rapid Micro Biosystems investor relations website and archived for 30 days post-event. Headquartered in Lowell, Massachusetts, the company focuses on modernizing microbial quality control testing in the pharmaceutical industry.
Rapid Micro Biosystems (Nasdaq: RPID) has announced the publication of a case study in the PDA Journal of Pharmaceutical Science and Technology, validating its automated colony counting technology for pharmaceutical microbiology. The research showcases the effectiveness of the Growth Direct system in enhancing quality control with faster results and improved accuracy. Conducted by eight global pharmaceutical firms, the study confirms compliance with regulatory standards. The Growth Direct system is already in routine use for multiple QC tests, supporting safe healthcare product releases.
Rapid Micro Biosystems (Nasdaq: RPID) announced the conclusion of its review of strategic alternatives, revealing that no binding offers were made for acquisition. The Board believes the best path forward is to enhance commercial execution and product development. The company plans to focus on its Growth Direct system, aiming to increase efficiency and customer experience. As of Q3 2022, RPID reported $150.1 million in cash with no debt, providing a cash runway into 2026. The Company continues investing in its solutions to drive growth and shareholder value.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) reported third quarter 2022 commercial revenue of $4.7 million, down from $6.3 million in Q3 2021. However, the company achieved a 34% year-over-year growth in recurring revenue, totaling $2.9 million. The company reaffirmed its full-year revenue guidance of at least $17 million, anticipating the placement of two additional systems in Q4. Despite a net loss of $16.3 million, improved cash reserves of $150.1 million and a comprehensive review of strategic alternatives aim to maximize shareholder value.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) will announce its third quarter 2022 financial results on November 10, 2022, before the market opens. Following the release, management will host a conference call at 8:30 a.m. EST. The company focuses on providing innovative automation solutions for the healthcare industry, including the Growth Direct System that modernizes microbial quality control testing. This advancement enhances efficiency and compliance, crucial for the safe production of healthcare products. For more details, visit the company's website.
Rapid Micro Biosystems (Nasdaq: RPID) has launched the RMBNucleus™ Mold Alarm, a new feature for the Growth Direct® System aimed at detecting environmental molds rapidly in pharmaceutical manufacturing. This innovation addresses the critical challenge of slow mold detection, which can jeopardize product safety. The Mold Alarm offers enhanced data integrity and alerts users within 24 hours of detection, allowing for prompt intervention. The product will be available before the end of 2022, and the company is showcasing it at the 2022 PDA Pharmaceutical Microbiology Conference.
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) announced its participation as a sponsor and exhibitor at the 2022 PDA Pharmaceutical Microbiology Conference, taking place from October 10-12 in Washington, D.C. The event will gather global professionals to discuss pharmaceutical microbiology challenges. The company will showcase its Growth Direct® System, an advanced automation platform for microbiological quality control, aimed at enhancing laboratory efficiency. Highlights include a Tech Talk on faster monitoring and two poster presentations focusing on compliance and automated differentiation in environmental tests.